{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:37:02Z","timestamp":1789799822234,"version":"4.0.1"},"reference-count":117,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"26","license":[{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,26]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>This study examines the role and function of the specific signaling molecules that are associated with the binding of sex hormone receptors, including estrogen receptor (ER) and progesterone receptor (PR), in relation to cell proliferation, differentiation, and survival. The present work focuses on the mutual relationship between signaling pathways of sex hormone receptors and MAPK and PI3K\/AKT pathways, as well as the involvement of these molecules in the development of breast cancer. The review systemizes the present knowledge regarding genetic changes related to breast cancer, including the effects of changes on sex hormone signaling, biochemical pathways influencing sex hormone availability, and epigenetic modifications. The focus is made on genetic changes the researchers observed in breast cancer, like ERBB2\/HER2 amplification and TP53 mutations, which cooperate with sex hormone signaling to advance tumor growth. The changes in the metabolism of sex hormones are as follows: High aromatase leading to high estrogen and more. Furthermore, the impact of sex steroids on the tumor microenvironment, including angiogenesis, immune regulation, and matrix, is consequently discussed. The effects of sex hormones on DNA methylation, histone modifications, and noncoding RNA with regard to breast cancer development are reviewed. The study also demonstrates how genetic changes, metabolism, and epigenetics work in concert with sex hormones to modulate breast cancer development. SERMs, aromatase inhibitors, and the endocrine approach are described, as well as novel directions to develop inhibitors of androgen and other hormone signaling pathways.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000049376","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T18:03:38Z","timestamp":1782497018000},"page":"e49376","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling the intricate molecular mechanisms of sex hormones\u2019 roles in breast cancer pathogenesis: A review"],"prefix":"10.1097","volume":"105","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3086-6369","authenticated-orcid":false,"given":"Matthew Chibunna","family":"Igwe","sequence":"first","affiliation":[{"name":"Department of Public Health, School of Allied Health Sciences, Kampala International University, Kansanga, Uganda"},{"name":"Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, College Medicine, Enugu State University of Science and Technology, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ogbonna Alphonsus","family":"Ogbuabor","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory Science, Faculty of Basic Medical Sciences, College Medicine, Enugu State University of Science and Technology, Enugu, Nigeria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon Ikechukwu","family":"Egba","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Research and Extension. Kampala International University, Kansanga, Uganda."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260915","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20260915","first-page":"861290","article-title":"Estrogen and progesterone signaling in breast cancer development.","volume":"12","author":"Zhou","year":"2022","journal-title":"Front Oncol"},{"key":"R3-20260915","first-page":"32","article-title":"Hormone receptor pathways and breast cancer metastasis.","volume":"518","author":"Singh","year":"2021","journal-title":"Cancer Lett"},{"key":"R4-20260915","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1470-2045(12)70425-4","article-title":"Menarche, menopause and breast cancer risk.","volume":"13","year":"2012","journal-title":"Lancet Oncol"},{"key":"R5-20260915","first-page":"1505","article-title":"TP53 and HER2 interactions in breast cancer progression.","volume":"44","author":"Wang","year":"2020","journal-title":"Oncol Rep"},{"key":"R6-20260915","first-page":"102","article-title":"Molecular targets of estrogen receptor signaling in breast cancer.","volume":"24","author":"Li","year":"2022","journal-title":"Breast Cancer Res"},{"key":"R7-20260915","first-page":"34","article-title":"Epigenetic regulation in breast cancer.","volume":"25","author":"Ahmed","year":"2023","journal-title":"Breast Cancer Res"},{"key":"R8-20260915","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/GRF.0000000000000239","article-title":"Breast cancer epidemiology and risk factors.","volume":"59","author":"Rojas","year":"2016","journal-title":"Clin Obstet Gynecol"},{"key":"R9-20260915","first-page":"1230","article-title":"Lifestyle and hormonal risk factors in breast cancer.","volume":"31","author":"Feng","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R10-20260915","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMp0708307","article-title":"\u201cWesternizing\u201d women\u2019s risks? Breast cancer in lower-income countries.","volume":"358","author":"Porter","year":"2008","journal-title":"N Engl J Med"},{"key":"R11-20260915","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"R12-20260915","doi-asserted-by":"crossref","first-page":"6834","DOI":"10.3390\/ijms24076834","article-title":"A basic review on estrogen receptor signaling pathways in breast cancer.","volume":"24","author":"Clusan","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R13-20260915","first-page":"186","article-title":"Priorities for the primary prevention of breast cancer.","volume":"64","author":"Colditz","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"R14-20260915","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/nature24284","article-title":"Association analysis identifies 65 new breast cancer risk loci.","volume":"551","author":"Michailidou","year":"2017","journal-title":"Nature"},{"key":"R15-20260915","first-page":"438","article-title":"Breast cancer statistics, 2019.","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"R16-20260915","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1210\/er.2015-1010","article-title":"EDC-2: the endocrine society\u2019s second scientific statement on endocrine-disrupting chemicals.","volume":"36","author":"Gore","year":"2015","journal-title":"Endocr Rev"},{"key":"R17-20260915","first-page":"213","article-title":"Pregnancy-induced protection against breast cancer.","volume":"13","author":"Russo","year":"2011","journal-title":"Breast Cancer Res"},{"key":"R18-20260915","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/bjsm.2006.029132","article-title":"Physical activity and breast cancer risk.","volume":"42","author":"Friedenreich","year":"2008","journal-title":"Br J Sports Med"},{"key":"R19-20260915","first-page":"1","article-title":"Melatonin, sleep disruption and cancer risk.","volume":"20","author":"Blask","year":"2009","journal-title":"Cancer Causes Control"},{"key":"R20-20260915","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome.","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"R21-20260915","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours.","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"key":"R22-20260915","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"R23-20260915","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumors.","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"R24-20260915","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/nature05887","article-title":"Genome-wide association study identifies novel breast cancer susceptibility loci.","volume":"447","author":"Easton","year":"2007","journal-title":"Nature"},{"key":"R25-20260915","first-page":"3328","article-title":"Polygenic risk scores for breast cancer prediction.","volume":"10","author":"Mavaddat","year":"2019","journal-title":"Nat Commun"},{"key":"R26-20260915","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","article-title":"Analysis of circulating tumor DNA to monitor metastatic breast cancer.","volume":"368","author":"Dawson","year":"2013","journal-title":"N Engl J Med"},{"key":"R27-20260915","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1056\/NEJMoa062790","article-title":"Mammographic density and the risk and detection of breast cancer.","volume":"356","author":"Boyd","year":"2007","journal-title":"N Engl J Med"},{"key":"R28-20260915","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nrendo.2010.87","article-title":"Environmental causes of breast cancer.","volume":"6","author":"Soto","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"R29-20260915","first-page":"12","article-title":"Molecular subtypes of breast cancer: review.","volume":"16","author":"Zhao","year":"2022","journal-title":"Breast Cancer Basic Clin Res"},{"key":"R30-20260915","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.cell.2010.03.015","article-title":"Matrix metalloproteinases: regulators of the tumor microenvironment.","volume":"141","author":"Kessenbrock","year":"2010","journal-title":"Cell"},{"key":"R31-20260915","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer.","volume":"5","author":"Prat","year":"2011","journal-title":"Mol Oncol"},{"key":"R32-20260915","first-page":"1","article-title":"Luminal B breast cancer: molecular features.","volume":"23","author":"Ades","year":"2014","journal-title":"Breast"},{"key":"R33-20260915","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1016\/S0140-6736(16)32417-5","article-title":"HER2-positive breast cancer.","volume":"389","author":"Loibl","year":"2017","journal-title":"Lancet"},{"key":"R34-20260915","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease.","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"R35-20260915","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer.","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"R36-20260915","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer.","volume":"62","author":"Osborne","year":"2011","journal-title":"Annu Rev Med"},{"key":"R37-20260915","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrc721","article-title":"Endocrine-responsive breast cancer and strategies for combating resistance.","volume":"2","author":"Ali","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"R38-20260915","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1210\/er.2004-0015","article-title":"Aromatase and breast cancer.","volume":"26","author":"Simpson","year":"2005","journal-title":"Endocr Rev"},{"key":"R39-20260915","first-page":"1341","article-title":"Aromatase inhibitors vs tamoxifen.","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"R40-20260915","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nrd1031","article-title":"Tamoxifen: a most unlikely pioneering medicine.","volume":"2","author":"Jordan","year":"2003","journal-title":"Nat Rev Drug Discov"},{"key":"R41-20260915","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/ng.2822","article-title":"ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.","volume":"45","author":"Toy","year":"2013","journal-title":"Nat Genet"},{"key":"R42-20260915","first-page":"310","article-title":"Elacestrant in ER-positive breast cancer.","volume":"388","author":"Bardia","year":"2023","journal-title":"N Engl J Med"},{"key":"R43-20260915","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/nature14583","article-title":"Progesterone receptor modulates ER\u03b1 action in breast cancer.","volume":"523","author":"Mohammed","year":"2015","journal-title":"Nature"},{"key":"R44-20260915","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1056\/NEJMra050776","article-title":"Estrogen carcinogenesis in breast cancer.","volume":"354","author":"Yager","year":"2006","journal-title":"N Engl J Med"},{"key":"R45-20260915","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/978-3-030-73119-9_21","article-title":"Progesterone receptor signaling in the breast tumor microenvironment.","volume":"1329","author":"Boonyaratanakornkit","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"R46-20260915","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene.","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"key":"R47-20260915","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/jnci\/djh166","article-title":"Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2\/neu cross-talk in ER\/HER2-positive breast cancer.","volume":"96","author":"Shou","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R48-20260915","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","article-title":"HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.","volume":"23","author":"Hanker","year":"2017","journal-title":"Clin Cancer Res"},{"key":"R49-20260915","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives.","volume":"9","author":"Arteaga","year":"2011","journal-title":"Nat Rev Clin Oncol"},{"key":"R50-20260915","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer.","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R51-20260915","doi-asserted-by":"crossref","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use.","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R52-20260915","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S0092-8674(00)81871-1","article-title":"p53, the cellular gatekeeper for growth and division.","volume":"88","author":"Levine","year":"1997","journal-title":"Cell"},{"key":"R53-20260915","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2641","article-title":"p53 mutations in cancer.","volume":"15","author":"Muller","year":"2013","journal-title":"Nat Cell Biol"},{"key":"R54-20260915","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ccell.2020.03.009","article-title":"Overcoming endocrine resistance in breast cancer.","volume":"37","author":"Hanker","year":"2020","journal-title":"Cancer Cell"},{"key":"R55-20260915","first-page":"114","article-title":"Role of coregulators in ER signaling.","volume":"10","author":"Osborne","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R56-20260915","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.celrep.2019.07.001","article-title":"Integrated analysis of TP53 gene and pathway alterations in The Cancer Genome Atlas.","volume":"28","author":"Donehower","year":"2019","journal-title":"Cell Rep"},{"key":"R57-20260915","first-page":"2549","article-title":"p53 regulation of estrogen receptor signaling.","volume":"32","author":"Berger","year":"2012","journal-title":"Mol Cell Biol"},{"key":"R58-20260915","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.7150\/thno.81847","article-title":"Role of p53 in breast cancer progression: an insight into p53 targeted therapy.","volume":"13","author":"Marvalim","year":"2023","journal-title":"Theranostics"},{"key":"R59-20260915","doi-asserted-by":"crossref","first-page":"3899","DOI":"10.3390\/cancers16233899","article-title":"Clinical relevance of TP53 mutation and its characteristics in breast cancer with long-term follow-up date.","volume":"16","author":"Hwang","year":"2024","journal-title":"Cancers"},{"key":"R60-20260915","first-page":"1","article-title":"The p53 pathway and cancer therapy.","volume":"16","author":"Levine","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"R61-20260915","first-page":"117","article-title":"Estrogen signaling and immune modulation in cancer.","volume":"1","author":"Thompson","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"R62-20260915","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1146\/annurev.pharmtox.40.1.581","article-title":"Human UDP-glucuronosyltransferases: metabolism, expression, and disease.","volume":"40","author":"Tukey","year":"2000","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R63-20260915","first-page":"322","article-title":"Sources of estrogen and androgen metabolism in cancer.","volume":"24","author":"Simpson","year":"2003","journal-title":"Endocr Rev"},{"key":"R64-20260915","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3389\/fimmu.2019.00348","article-title":"Immune tumor microenvironment in breast cancer and the participation of estrogen and its receptors in cancer physiopathology.","volume":"10","author":"Segovia-Mendoza","year":"2019","journal-title":"Front Immunol"},{"key":"R65-20260915","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s13046-020-01788-4","article-title":"The immunomodulatory effects of endocrine therapy in breast cancer.","volume":"40","author":"Huang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"key":"R66-20260915","doi-asserted-by":"crossref","first-page":"106517","DOI":"10.1016\/j.jsbmb.2024.106517","article-title":"Estrogen receptor regulation of the immune microenvironment in breast cancer.","volume":"240","author":"McGuinness","year":"2024","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R67-20260915","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.3390\/ijms25168604","article-title":"Inflammation and immune cell infiltration in breast cancer: role of estrogen and its receptors.","volume":"25","author":"McGuinness","year":"2024","journal-title":"Int J Mol Sci"},{"key":"R68-20260915","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41523-025-00875-z","article-title":"Heterogeneity and immune microenvironment of early invasive estrogen receptor-positive breast cancer reveal an immune-rich subset.","volume":"12","author":"Jain","year":"2026","journal-title":"npj Breast Cancer"},{"key":"R69-20260915","first-page":"104","article-title":"Expression of hormone receptors is associated with specific immunological profiles of the breast cancer microenvironment.","volume":"25","author":"Hanamura","year":"2023","journal-title":"Breast Cancer Res"},{"key":"R70-20260915","first-page":"10439","article-title":"Non-coding RNAs: multi-tasking molecules in the cell.","volume":"24","author":"Gomes","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R71-20260915","doi-asserted-by":"crossref","first-page":"3622","DOI":"10.3390\/cancers12123622","article-title":"Epigenetics in breast cancer therapy\u2014new strategies and future nanomedicine perspectives.","volume":"12","author":"Nassa","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R72-20260915","first-page":"3720","article-title":"Emerging role of epigenetic modifiers in breast cancer pathogenesis and therapeutic response.","volume":"14","author":"Zhang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R73-20260915","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1210\/me.2004-0486","article-title":"Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes.","volume":"19","author":"Bj\u00f6rnstr\u00f6m","year":"2005","journal-title":"Mol Endocrinol"},{"key":"R74-20260915","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1038\/s41467-022-30831-5","article-title":"YAP inhibits ER\u03b1 and ER+ breast cancer growth by disrupting a TEAD-ER\u03b1 signaling axis.","volume":"13","author":"Li","year":"2022","journal-title":"Nat Commun"},{"key":"R75-20260915","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.2005.10.036","article-title":"Estrogen-receptor biology: continuing progress and therapeutic implications.","volume":"23","author":"Osborne","year":"2005","journal-title":"J Clin Oncol"},{"key":"R76-20260915","first-page":"798","article-title":"Estrogen receptor-alpha phosphorylation and breast cancer.","volume":"71","author":"Weitsman","year":"2006","journal-title":"Steroids"},{"key":"R77-20260915","doi-asserted-by":"crossref","first-page":"867448","DOI":"10.3389\/fendo.2022.867448","article-title":"Decoding the therapeutic implications of the ER\u03b1 stability and subcellular distribution in breast cancer.","volume":"13","author":"Tecalco-Cruz","year":"2022","journal-title":"Front Endocrinol"},{"key":"R78-20260915","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1091\/mbc.e04-07-0547","article-title":"Palmitoylation-dependent estrogen receptor alpha membrane localization: regulation by 17beta-estradiol.","volume":"16","author":"Acconcia","year":"2005","journal-title":"Mol Biol Cell"},{"key":"R79-20260915","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.3390\/ijms24044043","article-title":"Emerging evidence on membrane estrogen receptors as novel therapeutic targets for central nervous system pathologies.","volume":"24","author":"Wnuk","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R80-20260915","doi-asserted-by":"crossref","first-page":"306","DOI":"10.3390\/ijms20020306","article-title":"G-Protein coupled estrogen receptor in breast cancer.","volume":"20","author":"Hsu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R81-20260915","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy.","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"R82-20260915","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3892\/ijmm.2014.1723","article-title":"ERK1\/2 pathway mediates epithelial-mesenchymal transition by cross-interacting with TGF-\u03b2\/Smad and Jagged\/Notch signaling pathways in lens epithelial cells.","volume":"33","author":"Chen","year":"2014","journal-title":"Int J Mol Med"},{"key":"R83-20260915","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.mce.2015.11.033","article-title":"GPER1-mediated IGFBP-1 induction modulates IGF-1-dependent signaling in tamoxifen-treated breast cancer cells.","volume":"422","author":"Vaziri-Gohar","year":"2016","journal-title":"Mol Cell Endocrinol"},{"key":"R84-20260915","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1210\/er.2006-0045","article-title":"Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance.","volume":"29","author":"Arpino","year":"2008","journal-title":"Endocr Rev"},{"key":"R85-20260915","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41420-023-01654-0","article-title":"GPER deletion triggers inhibitory effects in triple negative breast cancer (TNBC) cells through the JNK\/c-Jun\/p53\/Noxa transduction pathway.","volume":"9","author":"Cirillo","year":"2023","journal-title":"Cell Death Discov"},{"key":"R86-20260915","doi-asserted-by":"crossref","first-page":"1513225","DOI":"10.3389\/fonc.2025.1513225","article-title":"Decoding estrogen receptor and GPER biology: structural insights and therapeutic advances in ER\u03b1-positive breast cancer.","volume":"15","author":"Saha","year":"2025","journal-title":"Front Oncol"},{"key":"R87-20260915","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1210\/me.2004-0287","article-title":"Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology.","volume":"19","author":"Jacobsen","year":"2005","journal-title":"Mol Endocrinol"},{"key":"R88-20260915","first-page":"111212","article-title":"Progesterone receptors in breast cancer: novel roles in tumor progression, metastasis, and therapy resistance.","volume":"527","author":"Diep","year":"2021","journal-title":"Mol Cell Endocrinol"},{"key":"R89-20260915","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.mce.2009.01.004","article-title":"Signaling inputs to progesterone receptor gene regulation and promoter selectivity.","volume":"308","author":"Daniel","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"R90-20260915","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"R91-20260915","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nature09495","article-title":"RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.","volume":"468","author":"Gonzalez-Suarez","year":"2010","journal-title":"Nature"},{"key":"R92-20260915","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1038\/s41598-024-62664-1","article-title":"PIK3CA mutations in endocrine-resistant breast cancer.","volume":"14","author":"Schagerholm","year":"2024","journal-title":"Sci Rep"},{"key":"R93-20260915","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fonc.2014.00252","article-title":"The PTEN\/PI3K\/AKT pathway in vivo, cancer mouse models.","volume":"4","author":"Carnero","year":"2014","journal-title":"Front Oncol"},{"key":"R94-20260915","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1124\/pr.58.4.8","article-title":"International union of pharmacology. LXIV. estrogen receptors.","volume":"58","author":"Dahlman-Wright","year":"2006","journal-title":"Pharmacol Rev"},{"key":"R95-20260915","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1210\/me.2004-0390","article-title":"Integration of the extranuclear and nuclear actions of estrogen.","volume":"19","author":"Levin","year":"2005","journal-title":"Mol Endocrinol"},{"key":"R98-20260915","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1056\/NEJMoa1813904","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer.","volume":"380","author":"Andr\u00e9","year":"2019","journal-title":"N Engl J Med"},{"key":"R99-20260915","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"comprehensive review of HER2 in cancer biology and therapeutics.","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes (Basel)"},{"key":"R100-20260915","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s12943-017-0727-3","article-title":"Linc-RoR promotes MAPK\/ERK signaling and confers estrogen-independent growth of breast cancer.","volume":"16","author":"Peng","year":"2017","journal-title":"Mol Cancer"},{"key":"R102-20260915","first-page":"439","article-title":"Resistance to aromatase inhibitors is associated with a metabolically active phenotype in breast cancer cells.","volume":"23","author":"Simigdala","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"R103-20260915","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrendo.2011.122","article-title":"The G-protein-coupled estrogen receptor GPER in health and disease.","volume":"7","author":"Prossnitz","year":"2011","journal-title":"Nat Rev Endocrinol"},{"key":"R104-20260915","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.","volume":"366","author":"Baselga","year":"2012","journal-title":"N Engl J Med"},{"key":"R105-20260915","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1038\/sj.onc.1210394","article-title":"Integrating signals from RTKs to ERK\/MAPK.","volume":"26","author":"McKay","year":"2007","journal-title":"Oncogene"},{"key":"R106-20260915","first-page":"1","article-title":"Crosstalk in cell signaling: background noise or the real thing?","volume":"12","author":"Arnaldi","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"R107-20260915","doi-asserted-by":"crossref","first-page":"a007880","DOI":"10.1101\/cshperspect.a007880","article-title":"Frizzled and LRP5\/6 receptors for Wnt\/\u03b2-catenin signaling.","volume":"4","author":"MacDonald","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"R108-20260915","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease.","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"R109-20260915","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","article-title":"Shared principles in NF-kappaB signaling.","volume":"132","author":"Hayden","year":"2008","journal-title":"Cell"},{"key":"R110-20260915","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1095\/biolreprod.105.050070","article-title":"Membrane initiated estrogen signaling in breast cancer.","volume":"75","author":"Song","year":"2006","journal-title":"Biol Reprod"},{"key":"R111-20260915","first-page":"3636","article-title":"Niche control of cellular identity in cancer.","volume":"8","author":"Carver","year":"2009","journal-title":"Cell Cycle"},{"key":"R112-20260915","first-page":"1621","article-title":"Nongenomic actions of thyroid hormone: the integrin component.","volume":"99","author":"Davis","year":"2019","journal-title":"Physiol Rev"},{"key":"R113-20260915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/sj.bjp.0706736","article-title":"How corticosteroids control inflammation: quintiles prize lecture 2005.","volume":"148","author":"Barnes","year":"2006","journal-title":"Br J Pharmacol"},{"key":"R114-20260915","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s12015-007-0023-5","article-title":"Mammary stem cells and breast cancer\u2014role of Notch signalling.","volume":"3","author":"Farnie","year":"2007","journal-title":"Stem Cell Rev"},{"issue":"Suppl 1","key":"R115-20260915","first-page":"S269","article-title":"Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancer.","volume":"147","author":"Craig Jordan","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"4 Suppl 14","key":"R116-20260915","first-page":"3","article-title":"Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer.","volume":"29","author":"Miller","year":"2002","journal-title":"Semin Oncol"},{"key":"R117-20260915","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1200\/JCO.2016.71.3495","article-title":"Enzalutamide for the treatment of androgen receptor-expressing triple-negative breast cancer.","volume":"36","author":"Traina","year":"2018","journal-title":"J Clin Oncol"},{"key":"R118-20260915","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1634\/theoncologist.2017-0072","article-title":"Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 Results.","volume":"22","author":"Loibl","year":"2017","journal-title":"Oncologist"},{"key":"R119-20260915","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1158\/1078-0432.CCR-12-3327","article-title":"Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.","volume":"19","author":"Gucalp","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R120-20260915","first-page":"8659071","article-title":"Abiraterone acetate in combination with androgen receptor antagonist enzalutamide or antiestrogen fulvestrant exhibits activity in androgen receptor-positive triple-negative breast cancer.","volume":"2020","author":"Zhu","year":"2020","journal-title":"J Immunol Res"}],"updated-by":[{"DOI":"10.1097\/md.0000000000050689","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000}}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049376","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:12:17Z","timestamp":1789495937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000049376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,26]]},"references-count":117,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000049376","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,26]]},"assertion":[{"value":"2024-01-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}